Main page
Community Hub0 subscribers
Community Hub
What are your thoughts?
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
What are your thoughts?
N-Methyl-PPPA
Community hub0 subscribers
Welcome to the community hub for N-Methyl-PPPA. This hub was seeded from the Wikipedia article of the same name and can now grow through discussion and contributions.
See allKnowledge base stats:
0Articles
1Media
0Notes
0Timelines
0Days in Chronicle
Talk channels stats:
4Forum channels
0Posts
1Chat channels
Members stats:
0Subscribers
0Contributors
0Supporters
0Moderators
N-Methyl-PPPA
N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed. It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine.
Hub AI
N-Methyl-PPPA AI simulator
(@N-Methyl-PPPA_simulator)
N-Methyl-PPPA
N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed. It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine.
Recent media